EPISODE · May 13, 2026 · 18 MIN
CELMoDs for the treatment of relapsed/refractory MM
from Multiple Myeloma Hub
The Multiple Myeloma Hub spoke with Paul Richardson, Dana-Farber Cancer Institute, Boston, US. We asked about cereblon E3 ligase modulators (CELMoDs) for the treatment of relapsed/refractory multiple myeloma (RRMM). During this interview, Richardson reviews clinical data on the activity of CELMoDs, including mezigdomide and iberdomide, in RRMM. Richardson highlights response rates observed in ongoing studies, including activity in heavily pretreated and B-cell maturation antigen (BCMA)-exposed patients, as well as in extramedullary disease. Richardson also discusses safety findings, including hematologic toxicity and infection risk, and outlines emerging data on combination strategies and ongoing phase III trials. This educational resource is independently supported by BMS. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource. Hosted on Acast. See acast.com/privacy for more information.
What this episode covers
The Multiple Myeloma Hub spoke with Paul Richardson, Dana-Farber Cancer Institute, Boston, US. We asked about cereblon E3 ligase modulators (CELMoDs) for the treatment of relapsed/refractory multiple myeloma (RRMM). During this interview, Richardson reviews clinical data on the activity of CELMoDs, including mezigdomide and iberdomide, in RRMM. Richardson highlights response rates observed in ongoing studies, including activity in heavily pretreated and B-cell maturation antigen (BCMA)-exposed patients, as well as in extramedullary disease. Richardson also discusses safety findings, including hematologic toxicity and infection risk, and outlines emerging data on combination strategies and ongoing phase III trials. This educational resource is independently supported by BMS. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource. Hosted on Acast. See acast.com/privacy for more information.
NOW PLAYING
CELMoDs for the treatment of relapsed/refractory MM
No transcript for this episode yet
Similar Episodes
Apr 6, 2026 ·25m
Mar 30, 2026 ·27m